Herein, RET fusions defined a unique subset of alterations across multiple tumor types (>15 including NSCLC and multiple subtypes of thyroid cancer) targeted by pralsetinib, validating RET as a tissue-agnostic target. The gene discussed is RET; the disease is thyroid gland carcinoma.